10x Genomics

TXG Healthcare Medical Devices

10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.

Revenue
+1.12%
EPS
+31.8%
Free cash flow
−4.61%

Quarter to September 2026, against a year earlier

59.18 1.12 +1.93%
Market cap
$7.6B
P/E
0.0×
Fwd P/E
−95.9×
Dividend yield
—
F-score
6/9
Altman Z
3.99
Beneish M
−3.23
Dividend safety
n/a

10x Genomics 10-Q filed Nov 6, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 5:35 PM ET · Document on sec.gov · Filing index

Red flags

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 7, 2026: 3 added · 2 removed · 26 modified; 6 with only figures updated

  1. Modified · Overview

    We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. Our integrated research solutions include consist of instruments, consumables and software for analyzing biological systems at resolution and scale that matches the complexity of biology. Our commercial product portfolio is made up of across our Single Cell and Spatial solutionsportfolios. Our products include our instruments, which include our Chromium instruments, our Visium CytAssist for Single Cell and our Visium CytAssist, Xenium Analyzer, and our consumables, which Atera instruments for Spatial. Our consumables include proprietary microfluidic chips, slides, reagents and other consumables for used with our Single Cell Chromium, Visium, Xenium and SpatialAtera solutions. We bundle our software with these products to guidesupport customers through the workflow’ experiments, from sample preparation through data analysis and visualization. Customers purchase instruments and consumables from us for use in their experiments. We also derive revenue from post-warranty service contracts for our instruments.

30 more changes in this Item, word by word, in Powerpack.